The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with innovative therapies such as GLP-1 receptor agonists and multi-receptor agonists offering promising weight loss results. Recent clinical successes and regulatory approvals, including oral formulations and triple hormone receptor agonists, highlight growing demand for effective, convenient obesity treatments. This surge in R&D reflects obesity's rising global prevalence and the shift toward pharmacologic management of this chronic disease.
The surge in obesity treatment innovations is mirrored in the stock market activity of leading pharmaceutical companies. Eli Lilly (LLY) shares rose by 4.55% to USD 1,266.56, while Novo Nordisk (NVO) increased 3.75% to USD 39.55 as of Oct 16, 2026 00:22 WIB on Pluang. Despite Eli Lilly's large market cap of $1.08 trillion, Pluang investors show a stronger selling bias with 80% sell orders compared to Novo Nordisk's 32%, reflecting differing investor sentiment in the health sector.
Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor websi...
New data from Eli Lilly reveal that Omvoh (mirikizumab-mrkz) effectively achieves comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year of treatment. These outcomes, observed even...
Sangamo Therapeutics has initiated an auction process for its ST-503 program, a clinical-stage treatment targeting chronic neuropathic pain from small fiber neuropathy, with completion expected in Q4 2026. The program has FDA Fast Track status and sh...
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
